Factors Affecting Posterior Capsule Opacification in the Development of Intraocular Lens Materials.
clinical studies
experimental models
intraocular lenses
lens epithelial cells
pathophysiology
posterior capsule opacification
wound healing
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
10 Jun 2021
10 Jun 2021
Historique:
received:
09
05
2021
revised:
03
06
2021
accepted:
07
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Posterior capsule opacification (PCO) is the most common complication arising from the corrective surgery used to treat cataract patients. PCO arises when lens epithelial cells (LEC) residing in the capsular bag post-surgery undergo hyper-proliferation and transdifferentiation into myofibroblasts, migrating from the posterior capsule over the visual axis of the newly implanted intraocular lens (IOL). The developmental pathways underlying PCO are yet to be fully understood and the current literature is contradictory regarding the impact of the recognised risk factors of PCO. The aim of this review is firstly to collate the known biochemical pathways that lead to PCO development, providing an up-to-date chronological overview from surgery to established PCO formation. Secondly, the risk factors of PCO are evaluated, focussing on the impact of IOLs' properties. Finally, the latest experimental model designs used in PCO research are discussed to demonstrate the ongoing development of clinical PCO models, the efficacy of newly developed IOL technology, and potential therapeutic interventions. This review will contribute to current PCO literature by presenting an updated overview of the known developmental pathways of PCO, an evaluation of the impact of the risk factors underlying its development, and the latest experimental models used to investigate PCO. Furthermore, the review should provide developmental routes for research into the investigation of potential therapeutic interventions and improvements in IOL design in the aid of preventing PCO for new and existing patients.
Identifiants
pubmed: 34200928
pii: pharmaceutics13060860
doi: 10.3390/pharmaceutics13060860
pmc: PMC8230425
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : University of Brighton Scholarship with the Doctoral Training Alliance Bioscience Programme
ID : G2059
Références
J Cataract Refract Surg. 2001 Sep;27(9):1359-65
pubmed: 11566516
J Pak Med Assoc. 2008 Oct;58(10):550-2
pubmed: 18998307
J Transl Med. 2019 Jun 20;17(1):209
pubmed: 31221170
J Neurosci Res. 2004 Oct 15;78(2):151-6
pubmed: 15378607
Ophthalmology. 1996 Aug;103(8 Suppl):S5-16
pubmed: 8764763
Ophthalmic Surg Lasers Imaging. 2010 Nov-Dec;41(6):651-5
pubmed: 20954645
Prog Retin Eye Res. 2004 May;23(3):283-305
pubmed: 15177204
Ophthalmic Surg. 1991 Jun;22(6):358-9
pubmed: 1896178
Graefes Arch Clin Exp Ophthalmol. 2013 Jun;251(6):1529-40
pubmed: 23329402
Ophthalmic Epidemiol. 2004 Oct;11(4):319-29
pubmed: 15512993
J Cataract Refract Surg. 2004 Nov;30(11):2403-9
pubmed: 15519096
J Fr Ophtalmol. 2018 Dec;41(10):899-903
pubmed: 30473238
Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4679-87
pubmed: 17898292
Eye (Lond). 2006 Aug;20(8):949-51
pubmed: 16096657
Invest Ophthalmol Vis Sci. 2012 Apr 06;53(4):1835-45
pubmed: 22408013
PLoS One. 2013 Aug 02;8(8):e72772
pubmed: 23936544
Curr Opin Ophthalmol. 2006 Feb;17(1):31-41
pubmed: 16436922
Invest Ophthalmol Vis Sci. 2006 Jul;47(7):2985-9
pubmed: 16799043
Eye (Lond). 2018 Oct;32(10):1579-1589
pubmed: 29891902
Invest Ophthalmol Vis Sci. 2012 Jan 03;53(1):23-9
pubmed: 22125276
J Cell Mol Med. 2013 Jan;17(1):212-21
pubmed: 23205574
J Cell Sci. 2018 Nov 20;131(22):
pubmed: 30404825
Ophthalmic Res. 2010;44(4):225-36
pubmed: 20699626
Nippon Ganka Gakkai Zasshi. 1997 Dec;101(12):927-47
pubmed: 9436357
Cell Tissue Res. 2014 Jul;357(1):101-8
pubmed: 24793776
Biochem Biophys Rep. 2019 Oct 23;20:100696
pubmed: 31681860
Am J Ophthalmol. 2020 Jul;215:104-111
pubmed: 32061757
Eye Vis (Lond). 2017 Jun 26;4:16
pubmed: 28674696
Eye (Lond). 2020 Feb;34(2):225-231
pubmed: 31745327
Turk J Ophthalmol. 2016 Oct;46(5):205-208
pubmed: 28058161
Exp Eye Res. 2016 Jan;142:2-12
pubmed: 25939555
Invest Ophthalmol Vis Sci. 2002 Jul;43(7):2301-8
pubmed: 12091431
J Cataract Refract Surg. 2016 Mar;42(3):469-84
pubmed: 27063529
J Cataract Refract Surg. 2010 Jun;36(6):929-34
pubmed: 20494763
Br J Ophthalmol. 2007 Jul;91(7):912-5
pubmed: 17202203
Eur J Ophthalmol. 2004 Sep-Oct;14(5):375-80
pubmed: 15506598
Cell Cycle. 2019 Aug;18(15):1714-1726
pubmed: 31234714
Am J Ophthalmol. 2003 Oct;136(4):614-9
pubmed: 14516800
BMJ. 2006 Jul 15;333(7559):128-32
pubmed: 16840470
J Cataract Refract Surg. 1996;22 Suppl 1:852-8
pubmed: 9279684
J Ophthalmol. 2018 Oct 23;2018:8676451
pubmed: 30425856
Eye (Lond). 2014 Jun;28(6):720-7
pubmed: 24675577
Indian J Ophthalmol. 2020 May;68(5):785-786
pubmed: 32317446
Arch Ophthalmol. 2011 Jul;129(7):855-63
pubmed: 21402979
Ophthalmology. 2008 Aug;115(8):1308-14, 1314.e1-3
pubmed: 18321585
Ophthalmology. 2017 Mar;124(3):295-302
pubmed: 28065436
Immunol Rev. 2018 Jan;281(1):8-27
pubmed: 29247995
Invest Ophthalmol Vis Sci. 2014 May 20;55(7):4005-13
pubmed: 24845633
Invest Ophthalmol Vis Sci. 2019 Jan 2;60(1):113-122
pubmed: 30629726
Int J Nanomedicine. 2019 Nov 19;14:9047-9061
pubmed: 31819418
Exp Eye Res. 2009 Feb;88(2):257-69
pubmed: 19013456
Nepal J Ophthalmol. 2017 Jul;9(18):149-155
pubmed: 29634704
Curr Eye Res. 2013 Jan;38(1):86-90
pubmed: 22938910
Br J Clin Pharmacol. 2004 Jul;58(1):1-3
pubmed: 15206985
Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3591-3598
pubmed: 30025084
Eur J Pharm Biopharm. 2020 Apr;149:248-256
pubmed: 32112896
Clin Exp Ophthalmol. 2006 Aug;34(6):526-34
pubmed: 16925699
Can J Ophthalmol. 2009 Apr;44(2):165-70
pubmed: 19491950
Exp Eye Res. 2009 Aug;89(2):124-5
pubmed: 19254714
Invest Ophthalmol Vis Sci. 2009 Feb;50(2):752-9
pubmed: 19011011
Invest Ophthalmol Vis Sci. 2018 Oct 1;59(12):4986-4997
pubmed: 30326070
Br J Ophthalmol. 2000 Mar;84(3):332-6
pubmed: 10684849
J Cell Mol Med. 2017 May;21(5):916-928
pubmed: 27976512
Invest Ophthalmol Vis Sci. 1991 Apr;32(5):1534-9
pubmed: 2016135
PLoS One. 2016 Feb 03;11(2):e0148553
pubmed: 26840405
Curr Eye Res. 2018 Jun;43(6):702-708
pubmed: 29451997
Exp Eye Res. 2009 Nov;89(5):728-34
pubmed: 19583956
Front Pharmacol. 2017 Jul 14;8:461
pubmed: 28769795
Clin Med Res. 2006 Dec;4(4):294-309
pubmed: 17210978
Invest Ophthalmol Vis Sci. 1998 Jul;39(8):1410-8
pubmed: 9660489
Int J Ophthalmol. 2013 Dec 18;6(6):752-7
pubmed: 24392320
Vet Microbiol. 2017 Apr;202:2-15
pubmed: 27321134
Exp Eye Res. 2018 Jul;172:94-103
pubmed: 29617629
Acta Ophthalmol. 2018 Nov;96(7):e874-e882
pubmed: 29855160
Gene Ther. 2006 Mar;13(5):440-8
pubmed: 16251995
Exp Eye Res. 2015 Jul;136:100-15
pubmed: 25783492
Int J Mol Sci. 2019 Apr 27;20(9):
pubmed: 31035577
Biointerphases. 2007 Jun;2(2):89-94
pubmed: 20408641
Int J Biomed Sci. 2007 Dec;3(4):237-50
pubmed: 23675049
Dev Dyn. 2018 Mar;247(3):340-345
pubmed: 28480986
J Cataract Refract Surg. 2010 Mar;36(3):380-8
pubmed: 20202533
J Curr Ophthalmol. 2018 May 18;30(4):287-296
pubmed: 30555960
Arch Ophthalmol. 2009 Apr;127(4):555-62
pubmed: 19365040
Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2701-7
pubmed: 17525202
Br J Ophthalmol. 1996 Oct;80(10):906-10
pubmed: 8976703
Int J Ophthalmol. 2015 Aug 18;8(4):725-9
pubmed: 26309870
Invest Ophthalmol Vis Sci. 2008 May;49(5):1998-2003
pubmed: 18436832
Eye (Lond). 1999 Jun;13 ( Pt 3b):489-92
pubmed: 10627830
Int J Mol Sci. 2018 Oct 09;19(10):
pubmed: 30304871
J Cataract Refract Surg. 2000 Oct;26(10):1550-4
pubmed: 11033406
J Cataract Refract Surg. 2009 Mar;35(3):459-65
pubmed: 19251138
Transl Vis Sci Technol. 2018 Feb 28;7(1):21
pubmed: 29497583
Matrix Biol. 2020 Aug;90:79-108
pubmed: 32173580
J Ophthalmol. 2018 Mar 15;2018:2687385
pubmed: 29736282
BMC Ophthalmol. 2015 Jan 19;15:5
pubmed: 25599704
Lab Invest. 2006 Feb;86(2):106-15
pubmed: 16341020
Invest Ophthalmol Vis Sci. 1997 Feb;38(2):396-404
pubmed: 9040473
Indian J Ophthalmol. 2018 Sep;66(9):1272-1277
pubmed: 30127138
Biochem Biophys Res Commun. 2007 Feb 9;353(2):337-43
pubmed: 17187756
Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4260-6
pubmed: 16249506
Database (Oxford). 2016 Jul 03;2016:
pubmed: 27374120
Br J Ophthalmol. 1994 Dec;78(12):917-20
pubmed: 7819176
J Ocul Pharmacol Ther. 2020 Jan/Feb;36(1):56-64
pubmed: 31259661
Biomaterials. 2006 Nov;27(32):5554-60
pubmed: 16872673
Br J Ophthalmol. 1998 Apr;82(4):419-22
pubmed: 9640193
Graefes Arch Clin Exp Ophthalmol. 1999 Oct;237(10):806-11
pubmed: 10502054
Trends Microbiol. 2012 Jan;20(1):50-7
pubmed: 22153753
J Cataract Refract Surg. 1997 Dec;23(10):1539-42
pubmed: 9456413
Trans Ophthalmol Soc U K. 1964;84:5-14
pubmed: 5227439
Med Hypotheses. 2013 Apr;80(4):466-74
pubmed: 23375410
Exp Eye Res. 2018 Jun;171:101-105
pubmed: 29559302
J Cataract Refract Surg. 2008 Aug;34(8):1318-28
pubmed: 18655983
J Ophthalmol. 2018 Aug 5;2018:9089285
pubmed: 30174947
Mo Med. 2013 May-Jun;110(3):212-5
pubmed: 23829105
Int J Ophthalmol. 2018 Aug 18;11(8):1253-1257
pubmed: 30140626
BMC Ophthalmol. 2020 Feb 27;20(1):77
pubmed: 32103739
Eur J Ophthalmol. 2007 Jan-Feb;17(1):20-8
pubmed: 17294379
J Cataract Refract Surg. 1999 Nov;25(11):1486-91
pubmed: 10569163
Sci Rep. 2018 Aug 24;8(1):12739
pubmed: 30143742
J Ophthalmic Vis Res. 2015 Oct-Dec;10(4):370-4
pubmed: 27051480
J Cataract Refract Surg. 2001 Apr;27(4):608-13
pubmed: 11311632
Turk J Ophthalmol. 2017 Aug;47(4):221-225
pubmed: 28845327
Curr Mol Med. 2010 Aug;10(6):565-78
pubmed: 20642439
Medicine (Baltimore). 2017 Nov;96(44):e8301
pubmed: 29095259